Supernus Pharmaceuticals’ second-biggest moneymaker could grab Food and Drug Administration approval to treat bipolar disorder, an analyst suggested Thursday, prompting shares to a record high.
At the close on the stock market today, Supernus stock popped 3.1% to 38.75, after earlier rising as much as 4.3%. Shares lingered in a profit zone after hitting a 32.10 entry point out of an ascending base in mid-April.
